Proteins and Peptides

13 Apr 2022 Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
11 Apr 2022 Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
10 Apr 2022 WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated significant expansion of the therapeutic window, compared to recombinant IL-12, and generated potent
07 Apr 2022 Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
07 Apr 2022 ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
30 Mar 2022 Lannett Initiates Pivotal Clinical Trial For Biosimilar Insulin Glargine
29 Mar 2022 Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes
25 Mar 2022 Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin
24 Mar 2022 New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer
24 Mar 2022 Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
23 Mar 2022 Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis
22 Mar 2022 Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers
21 Mar 2022 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
17 Mar 2022 Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
16 Mar 2022 Omnix Medical Advances Novel Anti-Infective Program into Clinical Development
16 Mar 2022 PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy
16 Mar 2022 Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
15 Mar 2022 Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
12 Mar 2022 Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
10 Mar 2022 FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin
09 Mar 2022 Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
08 Mar 2022 Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA
05 Mar 2022 Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
27 Feb 2022 Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
24 Feb 2022 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up